New hope for brain tumor patients: targeted drug shows promise in early trial

This early-phase study tests a new drug, DS-1001b, in 47 people with a specific type of brain tumor (glioma) that has an IDH1 mutation and has come back after standard treatments. The main goal is to check the drug's safety and how the body processes it, while also looking for signs that it might shrink or control the tumor. Participants must have a confirmed IDH1 mutation and measurable tumor, but cannot have severe brain pressure or other active cancers.